Found 6 matching trials
This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C PHASE2 The objective of this trial is to investigate tolerability, safety, pharmac...
Show More Location
1241.25.002 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients PHASE3 The aim of this trial is to evaluate efficacy and safety of treatment with ...
Show More Location
1241.37.61002 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3 PHASE2 To assess the pharmacokenetic characteristics of 600 mg BID BI 207127 / 120...
Show More Location
1241.30.10003 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1 PHASE3 The aim of the study is to confirm efficacy of treatment for 16 and 24 week...
Show More Location
1241.20.00026 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients PHASE1 To evaluate the drug-drug interactions between BI 201335 and BI 207127 as w...
Show More Location
1241.27.0006 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2 PHASE3 The aim of the study is to confirm efficacy and safety of treatment with 60...
Show More Location
1241.36.00016 Boehringer Ingelheim Investigational Site
Learn More & Join Trial